Please Wait
Applying Filters...
Menu
Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 1Alliance revenue - Reblozyl

02 5Reblozyl

03 2Reblozyl

PharmaCompass

01

Brand Name : Reblozyl

Luspatercept-aamt

arrow
IOPC
Not Confirmed

02

Brand Name : Reblozyl

Luspatercept-aamt

arrow
IOPC
Not Confirmed

03

Brand Name : Reblozyl

Luspatercept-aamt

arrow
IOPC
Not Confirmed

04

Brand Name : Reblozyl

Luspatercept

arrow
IOPC
Not Confirmed

05

Brand Name : Reblozyl

Luspatercept-aamt

arrow
IOPC
Not Confirmed

06

Brand Name : Reblozyl

Luspatercept

arrow
IOPC
Not Confirmed

07

Brand Name : Alliance revenue - Reblozyl

Luspatercept

arrow
IOPC
Not Confirmed

Brand Name : Alliance revenue - Reblozyl

arrow
IOPC
Not Confirmed

Luspatercept

Main Therapeutic Indication : Oncology

Currency : USD

2024 Revenue in Millions : 371

2023 Revenue in Millions : 212

Growth (%) : 75

blank

08

Brand Name : Reblozyl

Luspatercept

arrow
IOPC
Not Confirmed